US court dismisses Lipitor whistleblower suit against Pfizer
This article was originally published in Scrip
Executive Summary
A US federal judge has granted Pfizer's request to dismiss a former employee's qui tam lawsuit alleging that the company pursued an "off-label marketing scheme" for its hypolipaemic Lipitor (atorvastatin), resulting in false claims being submitted for reimbursement by federal and state health programmes.